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Edited by Ned ManteiAbstract Brain-derived neurotrophic factor (BDNF) is secreted
as either a mature furin-processed form or an unprocessed pro-
form. Here, we characterise the extracellular processing of
pro-BDNF by the serine protease plasmin. Using recombinant
BDNF, maintained in the pro-form by site-directed mutagenesis
or inhibition of furin, we demonstrate that plasmin (but not re-
lated proteases) is a speciﬁc and eﬃcient activator of pro-BDNF.
The proteolytic cleavage site is identiﬁed as Arg125-Val, within
the consensus furin-cleavage motif (RVRR), generating an active
form that stimulated neurite outgrowth on TrkB-transfected
PC12 cells. Furthermore, we demonstrate that this processing
can also occur in the pericellular environment by the action of
cell-associated plasminogen activators.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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processing1. Introduction
The neurotrophins are a family of ﬁve structurally related
proteins (BDNF, nerve growth factor (NGF), NT-3, NT-4/5,
and NT-6) with established roles in the development, mainte-
nance and repair of the nervous system [1], and increasingly
recognised to have similar roles in the cardiovascular system
[2,3]. They signal through a dual-receptor system, involving
Trk receptors (A, B and C), selective for individual neurotro-
phins, and the pan-neurotrophin receptor p75NTR, thereby
mediating apoptotic as well as trophic signals [4].
Neurotrophins are translated as 30–35 kDa preproproteins
consisting of a preprodomain, a prodomain and a C-terminal
mature neurotrophin domain. The proproteins undergo intra-
cellular cleavage by furin-like proprotein convertases C-termi-
nally of the consensus sequence R–X–K/R–R, to produce
mature proteins that are subsequently secreted [5,6]. However,
pro-neurotrophins have been detected both in cell culture [6,7]
and in vivo [8], and shown to signal preferentially through
p75NTR to induce apoptosis [7,9]. The identiﬁcation of extra-
cellular proteolytic processing of the pro-neurotrophins NGF
and BDNF [7], has added a further level of complexity to thisAbbreviations: BDNF, brain-derived neurotrophic factor; wtBDNF,
wild-type BDNF; mtBDNF, mutated BDNF; NGF, nerve growth
factor; uPA, urokinase plasminogen activator; uPAR, uPA receptor;
Dec-RVKR-CMK, decanoyl-Arg-Val-Lys-Arg-chloromethylketone
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doi:10.1016/j.febslet.2008.02.026system, potentially representing a mechanism for the regula-
tion of neurotrophin activity.
These ﬁndings have redirected focus into investigating pro-
neurotrophins as functional ligands, and the proteases that
regulate their extracellular processing. Many extracellular pro-
teases are involved in controlling cell behaviour [10]. The plas-
minogen activation system plays a key role by generating the
broad-speciﬁcity serine protease plasmin, which has a wide
range of potential protein substrates [11]. In the pericellular
environment, the generation of plasmin is tightly regulated
by the interaction of the urokinase plasminogen activator
(uPA) with its cellular uPA receptor (uPAR) [11–13]. Plasmin
has trypsin-like primary speciﬁcity, cleaving after Lys/Arg res-
idues, but its extended substrate speciﬁcity is incompatible
with cleavage at the consensus furin-cleavage site [14].
Here, we characterise the proteolytic processing of pro-
BDNF by plasmin, using BDNF maintained in the pro-form,
either by mutagenesis of the furin-cleavage site or by inhibition
of furin. We ﬁnd that plasmin eﬃciently processes pro-BDNF
in a puriﬁed system, identify the unique plasmin-cleavage site
in pro-BDNF, and demonstrate that the plasmin-processed
form can activate TrkB. Furthermore, we show that processing
of pro-BDNF by plasmin also occurs in the pericellular envi-
ronment by the action of cell-associated plasminogen activa-
tors.2. Materials and methods
2.1. Cell culture
Drosophila Schneider 2 cells (S2) were grown in Schneiders Dro-
sophila medium (Invitrogen) with L-glutamine, 10% heat-inactivated
FBS at 27 C in air. The prostate cancer cell line PC3 was maintained
in RPMI 1640 with L-glutamine (Invitrogen), 10% FCS at 37 C/5%
CO2. PC12 cells stably transfected with TrkB were a gift from Dr.
David Dawbarn (University of Bristol, UK) and were maintained in
RPMI 1640, 10% horse serum, 5% FCS at 37 C/5% CO2.
2.2. Generation of BDNF expression plasmids
Human pre-proBDNF cDNA was subcloned into the insect expres-
sion vector pMT-V5/His (Invitrogen) at the SpeI–NotI restriction sites
of the polylinker region. The native stop codon was mutated to allow
expression of the epitope tag. A construct for the expression of furin-
cleavage-resistant pro-BDNF was generated from the resulting plas-
mid pMT-BDNF-V5/His using primers designed to mutate the RVRR
furin consensus site (residues 125–128) to RVAA by QuikChange Site-
Directed Mutagenesis (Stratagene). A further pro-BDNF mutant con-
struct with RVAA mutated to AVAA was generated from the original
mutant using the same method.
2.3. Protein expression in S2 cells
S2 cells were transfected using Cellfectin (Invitrogen), according to
the manufacturers recommendations and selected for stable expres-
sion. Expression was induced with 0.5 mM CuSO4 in serum-freeblished by Elsevier B.V. All rights reserved.
Fig. 1. Expression of pro-BDNF. Various forms of BDNF were
expressed in S2 cells, and conditioned medium analysed by Western
blotting for the C-terminal V5 epitope. (A) RVAA-mtBDNF, (B)
wtBDNF, (C) wtBDNF expressed in the presence of the furin inhibitor
Dec-RVKR-CMK. Mature BDNF has a mobility corresponding to a
molecular weight of 18 kDa, consistent with furin-processed V5/His
tagged protein (predicted molecular weight 17564 Da).
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ing wild-type BDNF (wtBDNF) were treated with 7.5 lM decanoyl-
Arg-Val-Lys-Arg-chloromethylketone (Dec-RVKR-CMK) (R&D
Systems) to inhibit furin activity. Cell lysates and media were collected
by centrifugation 48 h after induction and protein expression analysed
by SDS–PAGE followed by Western blotting using an anti-V5 mono-
clonal antibody (Invitrogen). Pro-BDNF was puriﬁed to homogeneity
using Ni-NTA resin (Qiagen, Crawley, UK) equilibrated in 50 mM
Na2H2PO4 pH 8.0, 300 mM NaCl, 10 mM imidazole. Conditioned
medium was applied to the column, washed and eluted with a linear
gradient of 10–250 mM imidazole. Fractions containing pro-BDNF
were pooled, dialysed against equilibration buﬀer and further puriﬁed
using the same procedure. The pooled pro-BDNF was dialysed against
PBS, and stored at a ﬁnal concentration of 25 lg/ml as determined by
BCA assay (Pierce).
2.4. Plasmin processing of pro-BDNF
RVAA-mtBDNF, puriﬁed by Ni-NTA aﬃnity chromatography
(Qiagen), was incubated with 5 nM plasmin (American Diagnostica,
Stamford, USA) at 37 C. Aliquots were removed at timed intervals
and the reaction halted by addition of 5· SDS–PAGE sample buﬀer
containing DTT and analysed by 12.5% SDS–PAGE followed by Wes-
tern blotting (anti-V5). S2 conditioned medium containing RVAA-
mtBDNF, AVAA-mtBDNF or wtBDNF expressed in the presence
Dec-RVKR-CMK, was incubated with varying concentrations of
plasmin (0–100 nM) for 0–30 min at 37 C. Plasmin processing was
analysed by Western blotting. For mass spectrometry analysis, SDS–
PAGE gels were Coomassie-stained, bands excised and subject to
in-gel tryptic digestion. Tryptic peptides were analysed on a Reﬂex
III MALDI-ToF instrument (Bruker UK Ltd., Coventry).
2.5. Cellular activation assays
PC3 cells were plated in 96-well plates at 5 · 104 cells/well. After
overnight incubation the medium was replaced and cells were treated
with mutated BDNF (mtBDNF) in the presence or absence of 5 nM
Lys-plasminogen (Enzyme Research Laboratories, Swansea, UK) for
10 min at 37 C. Each condition was replicated in the absence of cells
as a control. Medium was collected and subject to Western blot anal-
ysis (anti-V5).
2.6. Analysis of neurotrophin activity
TrkB-PC12 cells were plated in 96-well plates at 5000 cells/well.
Varying concentrations of puriﬁed BDNF preparations were added
and incubated for 48 h. Human recombinant BDNF (R&D Systems,
Abingdon, UK) served as a positive control. BDNF activity was as-
sessed by its ability to stimulate neurite outgrowth, using phase-con-
trast microscopy, and was quantiﬁed as the percentage of cells with
neurites greater than one cell-body in length. Data were analysed by
Students t-test.3. Results
3.1. BDNF protein expression
To investigate the extracellular processing of pro-BDNF, it
was necessary to produce a furin-cleavage resistant form of
BDNF that would allow its secretion in an unprocessed pro-
form. Arg127 and Arg128 at positions P2 and P1, respectively
(Schechter and Berger [15] nomenclature), of the consensus
furin-cleavage site were mutated to alanine (RVRR to RVAA).
Both wild-type and the furin-cleavage resistant mutant BDNF
(RVAA-mtBDNF) were successfully expressed using an induc-
ible vector in Drosophila S2 cells. The mutation of the furin-
cleavage site resulted in the expression of completely intact
proprotein (Fig. 1A), compared to the 50:50 ratio of mature
to pro-BDNF observed in S2 cells expressing wtBDNF
(Fig. 1B). Treatment of these cells with the membrane-perme-
able furin inhibitor Dec-RVKR-CMK at the time of induction
also led to the accumulation of unprocessed pro-BDNF in the
conditioned medium (Fig. 1C).3.2. Pro-BDNF processing by the serine protease plasmin
Puriﬁed furin-resistant RVAA-mtBDNF was incubated with
plasmin in solution. The pro-form was rapidly processed to an
18 kDa fragment at a low concentration of plasmin (Fig. 2).
This C-terminal fragment is equivalent in size to the furin-pro-
cessed, mature form of wtBDNF (Fig. 1B). The plasmin cleav-
age appears to be unique, as no other C-terminal fragments
were detected. Wild-type pro-BDNF expressed in the presence
of the furin inhibitor was also eﬃciently processed by plasmin
(data not shown). A range of other trypsin-like serine prote-
ases, including thrombin, hepsin and matriptase, did not pro-
cess pro-BDNF under similar conditions (data not shown).
3.3. Identiﬁcation of the plasmin cleavage site
To identify the plasmin cleavage site, RVAA-mtBDNF was
incubated with plasmin and the resultant fragments puriﬁed by
anion exchange chromatography, run on SDS–PAGE and the
18 kDa band excised. However, we were unable to determine
the identity of this fragment, either by N-terminal sequencing
or by MALDI-ToF mass spectrometry. Therefore, the frag-
ment was subjected to tryptic digestion prior to mass spec-
trometry. A peptide with mass 923.47 was identiﬁed,
consistent with the residues 126–134 of RVAA-mtBDNF
(VAAHSDPAR, theoretical mass 923.469). The presence of
this peptide indicates that the plasmin cleavage site is not
C-terminal to the Arg128 furin cleavage. Potential plasmin-
cleavage sites N-terminal of the furin consensus sequence oc-
cur at Lys76, Arg78, Lys85, Arg93 and Lys114, however cleavage
at these sites would generate fragments signiﬁcantly larger
than mature wtBDNF and no tryptic peptides N-terminal of
the 126–134 sequence were detected. These observations indi-
cated that the plasmin cleavage may occur at Arg125 within
the furin consensus sequence. To test this a second mutant,
AVAA-mt BDNF, was constructed with this residue substi-
tuted. This mutant was not processed to the 18 kDa fragment
by plasmin, under conditions in which RVAA-mtBDNF was
eﬃciently processed (Fig. 2B). These experiments demonstrate
that the preferential plasmin-cleavage site in pro-BDNF lies at
Arg125-Val126.
Fig. 2. Plasmin cleavage of pro-BDNF. (A) Puriﬁed RVAA-mtBDNF
was incubated in the presence or absence of plasmin (5 nM). (B)
Conditioned medium from RVAA-mtBDNF and AVAA-mtBDNF
were incubated with plasmin (20 nM). Aliquots were removed at the
indicated timed intervals and analysed by Western blotting (anti-V5).
The reduction in signal intensity observed in the presence of plasmin
with increasing incubation time is due to proteolytic cleavage of the
C-terminal epitope-tag.
Fig. 3. BDNF-mediated neurite outgrowth. TrkB-PC12 cells were
treated with various forms of BDNF for 48 h as indicated. Neurite
positive cells are expressed as a percentage of the total cell population.
Plasmin-cleaved RVAA-mtBDNF and mature wtBDNF were signif-
icantly diﬀerent to both control and RVAA-mtBDNF (*P < 0.05,
n = 4). The diﬀerence between mature wtBDNF and plasmin-cleaved
RVAA-mtBDNF was not statistically signiﬁcant.
Fig. 4. Cell surface activation of pro-BDNF. PC3 cells maintained in
SFM were incubated with RVAA-mtBDNF for 10 min either in the
absence (A) or presence (B) of plasminogen. Conditioned medium was
removed and BDNF processing analysed by Western blotting (anti-
V5).
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To test whether plasmin cleaved pro-BDNF has biological
activity equivalent to mature wtBDNF its ability to stimulate
neurite outgrowth in TrkB-expressing PC12 cells was deter-
mined. Cells were treated with mature wtBDNF, RVAA-
mtBDNF or plasmin-cleaved RVAA-mtBDNF, and neurite
outgrowth quantiﬁed after 48 h. These experiments show that
the plasmin-processed form of BDNF stimulates neurite out-
growth to a similar extent to mature wtBDNF, in contrast to
unprocessed pro-BDNF which had no signiﬁcant activity
(Fig. 3).
3.5. Cell surface activation of pro-BDNF
Having observed plasmin-mediated processing of pro-
BDNF in puriﬁed systems, we tested whether this could also
occur pericellularly. PC3 cells (which express both uPA and
uPAR) rapidly processed RVAA-mtBDNF to the active
18 kDa form in the presence of plasminogen (Fig. 4). Process-
ing was not observed in the absence of plasminogen, or in con-
ditioned medium, either in the presence or absence of
plasminogen. These data show that the activation of a low con-
centration of plasminogen by cell-associated plasminogen acti-
vators produces suﬃcient active plasmin to rapidly and
eﬃciently process pro-BDNF in the pericellular environment.
4. Discussion
Recent evidence suggests that a signiﬁcant proportion of
neurotrophins are secreted as unprocessed pro-forms, thatthe processed and unprocessed forms have diﬀering biological
activities, and that the pro-forms are susceptible to processing
by extracellular proteases. Here, we have produced intact
forms of pro-BDNF, both by mutation of the consensus fur-
in-cleavage site and by inhibition of furin activity. These
pro-forms were eﬃciently and speciﬁcally processed by plas-
min, requiring only a low concentration of protease and gener-
ating a single product similar in size to mature wtBDNF. The
speciﬁc plasmin-cleavage site was identiﬁed and found it to be
located within the consensus furin-cleavage sequence of
BDNF, but occurring after Arg125 rather than Arg128 of the
RVRR sequence. The P4-P1 sequence recognised by plasmin
(MSMR) is consistent with its known substrate preference
[14]. Interestingly, a SNP has been identiﬁed at Arg125
(Arg > Met) which would prevent plasmin processing.
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ing cells, stimulating neurite outgrowth, in contrast to the
much lower activity observed with pro-BDNF. The plasmin-
processed form characterised here is extended by three residues
at the N-terminus compared to furin-processed BDNF. The
crystal structure of mature BDNF shows that the six N-termi-
nal residues are disordered [16]. Although the BDNF Æ TrkB
complex has not been solved, the structure of NT-4/5 Æ TrkB
suggests that receptor binding leads to an ordering of the neu-
rotrophin N-terminus [17]. Consistent with this, mutations in
this region reduce neurotrophin activity, although only to a
minor degree [18].
We have also demonstrated that plasmin-processing of pro-
BDNF occurs via cell-associated plasminogen activators in the
pericellular environment, the primary site of plasminogen acti-
vation and plasmin activity in tissues [10–12]. A previous study
failed to observe pericellular processing of furin-resistant pro-
BDNF [19], however, Arg125 within the furin consensus motif
had been mutated to Ala, inadvertently destroying the plas-
min-cleavage site identiﬁed here. From the observed activity
of plasmin-processed BDNF against TrkB and the known
apoptotic eﬀects of pro-BDNF [9], this pericellular processing
would be expected to shift a pro-apoptotic response towards a
pro-survival eﬀect. The functional regulation of this system is
likely to be complex as, for example, activation of p75NTR,
the preferential receptor for pro-neurotrophins, can lead to a
reduction in plasmin generation [20], potentially suppressing
pericellular activation of the pro-forms.
How pro-BDNF evades intracellular processing is unknown,
however given that it has a distinct biological activity it is pos-
sible that this is a regulated process. It is notable that mutation
of a single cleavage site abolishes processing of BDNF,
whereas for NGF it is necessary to mutate three sites in order
to prevent processing [21]. Consistent with this, expression of
RKAA-mtNGF in S2 cells generates multiple partially pro-
cessed forms (Gray and Ellis, unpublished data). A variety
of proteins are produced as pro-forms that are subject to pro-
cessing by the furin-like proprotein convertases including
growth factors, receptors, cell adhesion molecules and matrix
metalloproteases [22]. If any of these occur as extracellular
proproteins requiring a proteolytic event to elaborate their
activity, plasmin may also be responsible for mediating the
activation of numerous, as yet unidentiﬁed proproteins.
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